Heterotopic heart transplantation: where do we stand?

被引:10
|
作者
Flecher, Erwan [1 ]
Fouquet, Olivier [2 ]
Ruggieri, Vito Giovanni [1 ]
Chabanne, Celine [1 ]
Lelong, Bernard [1 ]
Leguerrier, Alain [1 ]
机构
[1] Rennes Univ Hosp, Dept Cardiothorac & Vasc Surg, Rennes, France
[2] Angers Univ Hosp, Dept Cardiac Surg, Angers, France
关键词
Heterotopic; Orthotopic; Transplantation; FIXED PULMONARY-HYPERTENSION; CIRCULATORY SUPPORT; HEMODYNAMICS; PIONEER;
D O I
10.1093/ejcts/ezt136
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Orthotopic heart transplantation (OHT) is a well established and commonly utilized procedure for end-stage heart failure patients. Heterotopic heart transplantation (HHT) is a surgical procedure that allows the graft to be connected to the native heart in a parallel fashion. The main advantage of HHT is to assist the patient's native heart and to maintain circulation in the cases of severe acute rejection. HHT has also been proposed to overcome pulmonary hypertension, to increase the size of the donor pool and to decrease waiting times without increasing morbidity caused by the procedure. However, only a few papers have reported the short- or long-term results of HHT, and most of these studies have included <30 cases. OHT remains the standard technique and is preferable whenever the patient meets the current criteria and a suitable organ is available. HHT is far less useful than in the past because of the major advances in immunosuppression therapy and the development of long-term mechanical circulatory support. This study reviews the origin of HHT and discusses clinical developments, including their advantages and disadvantages.
引用
收藏
页码:201 / 206
页数:6
相关论文
共 50 条
  • [31] The total artificial heart: where have we been, where are we now, where are we going?
    Francisco A. Arabía
    Catherine Friederich Murray
    Indian Journal of Thoracic and Cardiovascular Surgery, 2023, 39 : 198 - 205
  • [32] Estimated glomerular filtration rate as an end point in kidney transplant trial: where do we stand
    Mariat, Christophe
    Maillard, Nicolas
    Phayphet, Manolie
    Thibaudin, Lise
    Laporte, Sylvi
    Alamartine, Eric
    Berthoux, Francois
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (01) : 33 - 38
  • [33] SARS-CoV-2 Infection in Transplant-Related Biology: Where Do We stand?
    Kong, Deqiang
    Li, Mingming
    Gong, Weihua
    ANNALS OF TRANSPLANTATION, 2020, 25 : 1 - 5
  • [34] Mesenchymal stromal cells in the treatment of graft-versus-host disease: where do we stand?
    Schuele, Silke
    Berger, Andre
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2015, 58 (11-12) : 1265 - 1273
  • [35] Interventions on Microbiota: Where Do We Stand on a Gut-Brain Link in Autism? A Systematic Review
    Prosperi, Margherita
    Santocchi, Elisa
    Guiducci, Letizia
    Frinzi, Jacopo
    Morales, Maria Aurora
    Tancredi, Raffaella
    Muratori, Filippo
    Calderoni, Sara
    NUTRIENTS, 2022, 14 (03)
  • [36] Heterotopic transplantation of heart and the regulatory mechanisms of the adaptation
    Baikov, A. N.
    Tolpekin, V. E.
    Medvedev, M. A.
    Semichiev, E., V
    Ivanov, S. D.
    BYULLETEN SIBIRSKOY MEDITSINY, 2016, 15 (03): : 5 - 9
  • [38] Osteopontin and Transplantation: Where Are We Now?
    Beata Kaleta
    Archivum Immunologiae et Therapiae Experimentalis, 2021, 69
  • [39] Permanent pacing for asystole of the donor heart after heterotopic heart transplantation
    Kalife, G
    Radovancevic, B
    Fighali, S
    TEXAS HEART INSTITUTE JOURNAL, 1997, 24 (01): : 64 - 67
  • [40] The Man with 2 Hearts: 25 Years from Heterotopic to Orthotopic Heart Transplantation
    Godfrey, Elizabeth L.
    Kueht, Michael L.
    Rana, Abbas
    Frazier, O. H.
    TEXAS HEART INSTITUTE JOURNAL, 2019, 46 (03): : 199 - 202